×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
EYPT – eyepoint, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
EYPT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/5
08:04 am
eypt
Eyepoint Pharmaceuticals (EYPT) had its price target raised by HC Wainwright from $23.00 to $30.00. They now have a "buy" rating on the stock.
High
Report
Eyepoint Pharmaceuticals (EYPT) had its price target raised by HC Wainwright from $23.00 to $30.00. They now have a "buy" rating on the stock.
3/5
03:02 am
eypt
EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... [Yahoo! Finance]
High
Report
EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising ... [Yahoo! Finance]
3/4
03:24 pm
eypt
Eyepoint Pharmaceuticals (EYPT) had its price target raised by Chardan Capital from $27.00 to $29.00. They now have a "buy" rating on the stock.
Low
Report
Eyepoint Pharmaceuticals (EYPT) had its price target raised by Chardan Capital from $27.00 to $29.00. They now have a "buy" rating on the stock.
3/4
12:52 pm
eypt
EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Medium
Report
EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/4
10:57 am
eypt
Eyepoint Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Eyepoint Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]
3/4
07:25 am
eypt
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments [Yahoo! Finance]
Low
Report
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments [Yahoo! Finance]
3/4
07:00 am
eypt
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
Low
Report
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments
3/2
07:13 am
eypt
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema [Yahoo! Finance]
Medium
Report
EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/5
04:06 pm
eypt
Form 10-K EyePoint, Inc. For: Dec 31
Low
Report
Form 10-K EyePoint, Inc. For: Dec 31
3/5
04:02 pm
eypt
Form 4 EyePoint, Inc. For: Mar 04 Filed by: Ribeiro Ramiro
Low
Report
Form 4 EyePoint, Inc. For: Mar 04 Filed by: Ribeiro Ramiro
3/4
07:05 am
eypt
Form 8-K EyePoint, Inc. For: Mar 04
Low
Report
Form 8-K EyePoint, Inc. For: Mar 04
3/2
07:06 am
eypt
Form 8-K EyePoint, Inc. For: Feb 26
Medium
Report
Form 8-K EyePoint, Inc. For: Feb 26
2/24
04:01 pm
eypt
Form SCHEDULE 13G EyePoint, Inc. Filed by: Paradigm Biocapital Advisors LP
Medium
Report
Form SCHEDULE 13G EyePoint, Inc. Filed by: Paradigm Biocapital Advisors LP
2/18
04:07 pm
eypt
Form 4 EyePoint, Inc. For: Feb 17 Filed by: Ribeiro Ramiro
Low
Report
Form 4 EyePoint, Inc. For: Feb 17 Filed by: Ribeiro Ramiro
2/17
04:26 pm
eypt
Form SCHEDULE 13G/A EyePoint, Inc. Filed by: TCG Crossover GP II, LLC
Medium
Report
Form SCHEDULE 13G/A EyePoint, Inc. Filed by: TCG Crossover GP II, LLC
2/12
09:08 am
eypt
Form SCHEDULE 13G/A EyePoint, Inc. Filed by: Adage Capital Management, L.P.
Low
Report
Form SCHEDULE 13G/A EyePoint, Inc. Filed by: Adage Capital Management, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/23
EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues
23.6%
4/28 Form 8-K EyePoint Pharmaceuticals For: Apr 22 10.8%
10/17 Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 10.0%
4/6 Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) was downgraded by analysts at B. Riley from a "buy" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $4.00. 9.3%
10/15 Form 4 EyePoint Pharmaceuticals For: Oct 12 Filed by: Paggiarino Dario A. 8.4%
9/11 Eyepoint +1.9% as Guggenheim starts at Buy [Seeking Alpha] 7.1%
3/13 Form 4 EyePoint Pharmaceuticals For: Mar 12 Filed by: Elston George 7.0%
11/27 Form 8-K EyePoint Pharmaceuticals For: Nov 27 5.5%
8/7 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.130 ActVsEst 0.020 - Beat 5.1%
11/1 EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU® 4.9%
4/28 Form 8-K EyePoint Pharmaceuticals For: Apr 22 10.8%
10/17 Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 10.0%
4/6 Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) was downgraded by analysts at B. Riley from a "buy" rating to a "neutral" rating. They now have a $1.00 price target on the stock, down previously from $4.00. 9.3%
10/15 Form 4 EyePoint Pharmaceuticals For: Oct 12 Filed by: Paggiarino Dario A. 8.4%
9/11 Eyepoint +1.9% as Guggenheim starts at Buy [Seeking Alpha] 7.1%
3/13 Form 4 EyePoint Pharmaceuticals For: Mar 12 Filed by: Elston George 7.0%
11/27 Form 8-K EyePoint Pharmaceuticals For: Nov 27 5.5%
8/7 Q2/2019 6/30/2019 EPS -0.110 ZacksConsensus -0.130 ActVsEst 0.020 - Beat 5.1%
11/1 EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU® 4.9%
TOP News Decliners
11/7
Q3/2019 9/30/2019 EPS -0.150 ZacksConsensus -0.140 ActVsEst (0.010) - Miss
-31.1%
2/20 EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock -20.8%
7/25 EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS) -16.4%
7/30 EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists -15.2%
11/9 Edited Transcript of EYPT earnings conference call or presentation 7-Nov-19 1:30pm GMT [Yahoo! Finance News] -13.5%
3/16 Form 10-K EyePoint Pharmaceuticals For: Dec 31 -13.1%
11/7 EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.7%
4/1 EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update -12.3%
3/5 EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress -9.7%
2/4 Form 8-K EyePoint Pharmaceuticals For: Feb 03 -8.5%
2/20 EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock -20.8%
7/25 EyePoint Pharmaceuticals Announces Early Assignment of Permanent and Specific J-Code J7314 for YUTIQ® by the Center for Medicare and Medicaid Services (CMS) -16.4%
7/30 EyePoint Pharmaceuticals Presents Positive Data Showcasing YUTIQ® at the 37th Annual Scientific Meeting of the American Society of Retina Specialists -15.2%
11/9 Edited Transcript of EYPT earnings conference call or presentation 7-Nov-19 1:30pm GMT [Yahoo! Finance News] -13.5%
3/16 Form 10-K EyePoint Pharmaceuticals For: Dec 31 -13.1%
11/7 EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] -12.7%
4/1 EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update -12.3%
3/5 EyePoint Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Corporate Progress -9.7%
2/4 Form 8-K EyePoint Pharmaceuticals For: Feb 03 -8.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: